The Foundation presents the results of AMBAR at the EADC
A delegation from Fundació ACE participated this week in the biannual meeting of the European Alzheimer's Disease Consortium (EADC) in Leipzig (Germany). At the meeting, that took place on April 11th -12th, the foundation presented the results of the AMBAR study (Alzheimer Management by Albumin Replacement), a clinical trial for the treatment of Alzheimer's.
AMBAR is an innovative study in development, led by the company Grifols, which opens a possible new treatment pathway for Alzheimer's disease. The study, in which Fundació ACE participates as a coordinating entity, is based on the hypothesis that most of the beta-amyloid, one of the proteins accumulated in the brains of Alzheimer's patients, is bound to another protein called albumin and circulates in plasma.
Extracting this plasma may flush amyloid-beta peptide from the brain into the plasma, thus limiting the disease's impact on the patient's cognitive functions.
Results of the AMBAR study
A positive effect of the treatment is observed in all the cognitive aspects analyzed so far in the clinical trial, for all patients, both mild and moderate, treated as a whole.
In addition, in some relevant areas, such as language and processing speed, not only is a slowdown in disease progression demonstrated, but there is a statistically significant improvement compared to patients in the placebo group, who exhibit the impairment of the disease itself.
The AMBAR study included 496 mild and moderate Alzheimer patients, randomized in three treatment groups and one control (placebo) group.
European Alzheimer's Disease Consortium
The EADC is a network of more than 50 European clinical and biomedical research centers in the field of Alzheimer's disease and other related dementias. Financed by the European Commission, the meeting gathers twice a year research centers from more than 20 countries.